Date: 2011-03-30
Type of information: R&D agreement
Compound: novel small molecule hits against an undisclosed drug target
Company: NovAliX (France) Graffinity Pharmaceuticals (Germany) Shionogi (Japan)
Therapeutic area: undisclosed
Type agreement: R&D
Action mechanism:
Disease: undisclosed
Details: Graffinity Pharmaceuticals GmbH, a member of the NovAliX group of companies, has entered into a research collaboration with Shionogi. Under the terms of the agreement, Graffinity will receive technology access fees and payments for follow-up chemistry for the generation of various, novel small molecule hits against a key drug target.
This marks the company first collaboration with a leading Japanese pharmaceutical company. Graffinity’s fragment screening platform combines chemical microarrays with a proprietary method for the standardized, label-free detection of compound-protein interactions via SPR-imaging. The company’s rapid and scalable drug discovery technology explores a rich chemical universe to identify drug fragments which address challenging drug targets. With its 110,000-compound library that contains 24,000 true fragments, Graffinity possesses one of the most diverse fragment libraries.
Financial terms: Financial details of the transaction were not disclosed.
Latest news:
